Teachers Retirement System of The State of Kentucky Sells 327 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Teachers Retirement System of The State of Kentucky lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 1.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,921 shares of the company’s stock after selling 327 shares during the quarter. Teachers Retirement System of The State of Kentucky owned approximately 0.08% of Omnicell worth $4,392,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Covestor Ltd bought a new stake in Omnicell during the 4th quarter worth about $29,000. Spire Wealth Management bought a new stake in Omnicell during the 1st quarter worth about $25,000. Elequin Capital LP bought a new stake in Omnicell during the 1st quarter worth about $30,000. Sageworth Trust Co grew its holdings in Omnicell by 2,173.9% during the 1st quarter. Sageworth Trust Co now owns 1,046 shares of the company’s stock worth $135,000 after acquiring an additional 1,000 shares during the last quarter. Finally, ARK Investment Management LLC grew its holdings in Omnicell by 29.3% during the 1st quarter. ARK Investment Management LLC now owns 1,404 shares of the company’s stock worth $182,000 after acquiring an additional 318 shares during the last quarter.

Insiders Place Their Bets

In other Omnicell news, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the sale, the chief executive officer now directly owns 302,049 shares in the company, valued at approximately $33,539,520.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the completion of the transaction, the chief executive officer now directly owns 302,049 shares of the company’s stock, valued at approximately $33,539,520.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Peter J. Kuipers sold 11,000 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the completion of the transaction, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at $6,496,263.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,500 shares of company stock worth $4,287,245. Company insiders own 2.76% of the company’s stock.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $95.27 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.11 and a quick ratio of 1.71. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 75.61, a P/E/G ratio of 2.65 and a beta of 1.06. The firm’s 50 day simple moving average is $107.22 and its 200 day simple moving average is $115.00. Omnicell, Inc. has a fifty-two week low of $94.78 and a fifty-two week high of $187.29.

Omnicell (NASDAQ:OMCLGet Rating) last announced its earnings results on Thursday, August 4th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.01). The company had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the business posted $0.71 earnings per share. As a group, sell-side analysts forecast that Omnicell, Inc. will post 2.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OMCL. BTIG Research cut their target price on shares of Omnicell from $190.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, July 27th. KeyCorp began coverage on shares of Omnicell in a research report on Thursday. They set an “overweight” rating and a $130.00 target price on the stock. Bank of America began coverage on shares of Omnicell in a research report on Friday, September 9th. They set a “buy” rating and a $120.00 target price on the stock. SVB Leerink began coverage on shares of Omnicell in a research report on Friday, July 15th. They set a “market perform” rating and a $124.00 target price on the stock. Finally, Piper Sandler cut their target price on shares of Omnicell from $162.00 to $150.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $151.71.

Omnicell Profile

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

See Also

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.